SynthesisMolecular neurobiology2026
A Systematic Review of Stem Cell Secretome-Derived Exosomes for Neuropathic Pain: Therapeutic Mechanisms and Translational Potential.
Synthesis in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropathic pain (NP) is a chronic disabling disorder with limited effective therapies. Exosomes isolated from the stem cell secretome have emerged as promising candidates because of their anti-inflammatory and neuroregenerative properties. This systematic review evaluated the mechanisms and translational potential of stem cell secretome-derived exosomes for NP. Following PRISMA 2020 guidelines, biomedical databases were searched from inception to Aug 2026. Eligible studies included preclinical and clinical investigations evaluating stem cell secretome-derived exosomes in NP models. Risk of bias was assessed using SYRCLE and RoB 2 or ROBINS-I. Because of substantial heterogeneity, a narrative synthesis was performed. Seventeen studies met the inclusion criteria, including 16 preclinical studies and one pilot clinical study. Most studies investigated mesenchymal stem cell secretome-derived exosomes and demonstrated reductions in pain-related behaviors across chronic constriction injury, diabetic peripheral neuropathy, and chemotherapy-induced peripheral neuropathy models. Therapeutic effects were associated with suppression of neuroinflammatory cytokines, inhibition of microglial activation, enhancement of neurotrophic signaling, and modulation of nuclear factor kappa B (NF-κB) and NOD-like receptor pyrin domain-containing 3 (NLRP3) pathways. The pilot clinical study suggested a favorable safety profile and potential benefit, although human evidence remains insufficient to establish clinical efficacy. Overall methodological quality was moderate, with heterogeneity in stem cell sources, exosome isolation methods, dosing strategies, administration routes, and outcome measures, precluding meta-analysis. Current evidence supports the biological plausibility of stem cell secretome-derived exosomes as emerging candidates for NP; however, randomized clinical trials and standardized vesicle characterization are required to establish efficacy and translational applicability.
Indexed as
Identifiers
42837065What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.